New insights into the mechanism of narrow-band UVB therapy for psoriasis

Journal of Investigative Dermatology

Volumn 130, Issue 11, 2010, Pages 2534-

  Keaney, Terrence C ^a   Kirsner, Robert S ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL FACTOR; CYCLOSPORIN; INTERLEUKIN 17; INTERLEUKIN 23; KERATIN;

CELL PROLIFERATION; DRUG DESIGN; DRUG EFFICACY; EPIDERMIS; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATION; NARROW BAND ULTRAVIOLET B THERAPY; NOTE; PATHOGENESIS; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TREATMENT OUTCOME;

EID: 77957947365     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2010.287     Document Type: Note

References (7)

1. DiSepio D, Chandraratna RA (2000) New drugs in the treatment of psoriasis. Expert Opin Investig Drugs 9:79-93
2. Ellis CN, Gorsulowsky DC, Hamilton TA et al. (1986) Cyclosporine improves psoriasis in a double-blind study. JAMA 256:3110-6
3. Johnson-Huang lM, Suárez-Fariñas M, Sullivan-Whalen M et al. (2010) Effective narrow-band uVb radiation therapy suppresses the Il-23/Il-17 axis in normalized psoriasis plaques. J Invest Dermatol, 130, 2654-63
4. Johnston A, Gudjonsson JE, Sigmundsdottir H et al. (2005) The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol 114:154-63
5. Lee E, Trepicchio WL, Oestreicher JL et al. (2004) Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 199:125-30
6. Lowes MA, Kikuchi T, Fuentes-Duculan J et al. (2008) Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 128:1207-11
7. Papp KA, Langley RG, Lebwohl M et al. (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371:1675-84